UY27588A1 - Lactamas como antagonistas de taquiquininas - Google Patents
Lactamas como antagonistas de taquiquininasInfo
- Publication number
- UY27588A1 UY27588A1 UY27588A UY27588A UY27588A1 UY 27588 A1 UY27588 A1 UY 27588A1 UY 27588 A UY27588 A UY 27588A UY 27588 A UY27588 A UY 27588A UY 27588 A1 UY27588 A1 UY 27588A1
- Authority
- UY
- Uruguay
- Prior art keywords
- preparation
- antagonists
- taquiquinine
- lactamas
- lactemas
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 3
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 102000008186 Collagen Human genes 0.000 abstract 1
- 108010035532 Collagen Proteins 0.000 abstract 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 abstract 1
- 241000590002 Helicobacter pylori Species 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 abstract 1
- 208000025747 Rheumatic disease Diseases 0.000 abstract 1
- 102000003141 Tachykinin Human genes 0.000 abstract 1
- 108010046334 Urease Proteins 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 229940037467 helicobacter pylori Drugs 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 150000003951 lactams Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 230000000552 rheumatic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000001148 spastic effect Effects 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 108060008037 tachykinin Proteins 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Lactemas como antagonistas de taquiquininas . Esta invención se refiere a compuestos de fórmulas I: o una sal profármaco, solvato o polimorfo farmacéuticamente aceptable del mismo, agente terapéutico de la familia de la lactama y procesos para su preparación, intermedio utilizados en su preparación, composiciones que los contienen y usos de dichos derivados, útiles para prevenir o tratar enfermedades: inflamatorias, enfermedades causadas por helicobacter pylori u otras bacterias gran negativas positivas de ureasa, afecciones urológicas, alergia, vaso espástica, fibrosante o del colágeno, distrofia simpática refleja, neuropatia periférica, reumática oftálmica, dolor agudo o crónico o enfermedad viral, y trastornos: del sistema nervioso central (SNC), gastrointestinal (gi) , pulmonar, de relacionado con estres, neuropatológico, trastorno relacionado con potenciación o supresión inmunes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0130261.1A GB0130261D0 (en) | 2001-12-18 | 2001-12-18 | Lactams as tachykinin antagonists |
| US35081102P | 2002-01-22 | 2002-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY27588A1 true UY27588A1 (es) | 2003-07-31 |
Family
ID=9927858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY27588A UY27588A1 (es) | 2001-12-18 | 2002-12-17 | Lactamas como antagonistas de taquiquininas |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7060836B2 (es) |
| EP (1) | EP1456200A1 (es) |
| JP (1) | JP2005514389A (es) |
| AR (1) | AR037852A1 (es) |
| AU (1) | AU2002366320A1 (es) |
| BR (1) | BR0215017A (es) |
| CA (1) | CA2470236A1 (es) |
| GB (1) | GB0130261D0 (es) |
| GT (1) | GT200200280A (es) |
| HN (1) | HN2002000365A (es) |
| MX (1) | MXPA04005221A (es) |
| PA (1) | PA8561501A1 (es) |
| PE (1) | PE20030718A1 (es) |
| TW (1) | TW200302097A (es) |
| UY (1) | UY27588A1 (es) |
| WO (1) | WO2003051868A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7199250B2 (en) | 2002-12-20 | 2007-04-03 | Battelle Memorial Institute | Process for producing cyclic compounds |
| FR2873373B1 (fr) * | 2004-07-23 | 2006-09-08 | Sanofi Synthelabo | Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique |
| TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| WO2006058294A2 (en) * | 2004-11-29 | 2006-06-01 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| EP1863490A2 (en) * | 2005-03-28 | 2007-12-12 | Vertex Pharmaceuticals Incorporated | Muscarinic modulators |
| US8193208B2 (en) | 2005-09-09 | 2012-06-05 | Purdue Pharma L.P. | Fused and spirocycle compounds and the use thereof |
| WO2007086559A1 (ja) * | 2006-01-27 | 2007-08-02 | Ube Industries, Ltd. | テトラヒドロピラン化合物の製造方法 |
| WO2007110449A1 (en) | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| WO2007118853A1 (en) * | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| TW200812963A (en) | 2006-04-13 | 2008-03-16 | Euro Celtique Sa | Benzenesulfonamide compounds and the use thereof |
| EP2021005A4 (en) * | 2006-05-03 | 2009-11-25 | Cnsbio Pty Ltd | METHOD AND COMPOSITION FOR THE TREATMENT OF INFLAMMATORY PAIN |
| WO2008124118A1 (en) | 2007-04-09 | 2008-10-16 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use therof |
| US7592345B2 (en) * | 2007-06-13 | 2009-09-22 | Hoffmann-La Roche Inc. | Piperazine and [1,4]diazepan derivatives as NK antagonists |
| EP2175886A1 (en) * | 2007-06-28 | 2010-04-21 | CNSBio Pty Ltd | Combination methods and compositions for treatment of neuropathic pain |
| WO2009033995A1 (en) * | 2007-09-14 | 2009-03-19 | F. Hoffmann-La Roche Ag | Piperidine derivatives as nk3 receptor antagonists |
| US8765736B2 (en) | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| PL3290415T3 (pl) * | 2011-03-23 | 2021-07-19 | Trevena, Inc. | Ligandy receptora opioidowego oraz sposoby ich stosowania i wytwarzania |
| CA3007020A1 (en) | 2015-12-14 | 2017-06-22 | Trevena, Inc. | Methods of treating hyperalgesia |
| WO2017126635A1 (ja) * | 2016-01-22 | 2017-07-27 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN112321599B (zh) * | 2020-11-25 | 2023-05-30 | 合肥远志医药科技开发有限公司 | 一种药物中间体7-氧代-2-氮杂螺[3.5]壬烷的合成方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW432061B (en) * | 1994-08-09 | 2001-05-01 | Pfizer Res & Dev | Lactams |
| GB9600235D0 (en) * | 1996-01-05 | 1996-03-06 | Pfizer Ltd | Therapeutic agents |
-
2001
- 2001-12-18 GB GBGB0130261.1A patent/GB0130261D0/en not_active Ceased
-
2002
- 2002-12-06 BR BR0215017-4A patent/BR0215017A/pt not_active IP Right Cessation
- 2002-12-06 CA CA002470236A patent/CA2470236A1/en not_active Abandoned
- 2002-12-06 AU AU2002366320A patent/AU2002366320A1/en not_active Abandoned
- 2002-12-06 WO PCT/IB2002/005234 patent/WO2003051868A1/en not_active Ceased
- 2002-12-06 JP JP2003552752A patent/JP2005514389A/ja not_active Withdrawn
- 2002-12-06 EP EP02804985A patent/EP1456200A1/en not_active Withdrawn
- 2002-12-06 MX MXPA04005221A patent/MXPA04005221A/es not_active Application Discontinuation
- 2002-12-12 PA PA20028561501A patent/PA8561501A1/es unknown
- 2002-12-12 PE PE2002001201A patent/PE20030718A1/es not_active Application Discontinuation
- 2002-12-16 AR ARP020104878A patent/AR037852A1/es not_active Application Discontinuation
- 2002-12-16 HN HN2002000365A patent/HN2002000365A/es unknown
- 2002-12-17 GT GT200200280A patent/GT200200280A/es unknown
- 2002-12-17 US US10/322,068 patent/US7060836B2/en not_active Expired - Fee Related
- 2002-12-17 UY UY27588A patent/UY27588A1/es not_active Application Discontinuation
- 2002-12-17 TW TW091136374A patent/TW200302097A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20040132710A1 (en) | 2004-07-08 |
| CA2470236A1 (en) | 2003-06-26 |
| TW200302097A (en) | 2003-08-01 |
| GB0130261D0 (en) | 2002-02-06 |
| JP2005514389A (ja) | 2005-05-19 |
| WO2003051868A1 (en) | 2003-06-26 |
| HN2002000365A (es) | 2003-07-23 |
| MXPA04005221A (es) | 2004-08-19 |
| EP1456200A1 (en) | 2004-09-15 |
| PA8561501A1 (es) | 2003-07-28 |
| GT200200280A (es) | 2003-07-11 |
| AU2002366320A1 (en) | 2003-06-30 |
| BR0215017A (pt) | 2004-08-31 |
| PE20030718A1 (es) | 2003-08-18 |
| AR037852A1 (es) | 2004-12-09 |
| US7060836B2 (en) | 2006-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY27588A1 (es) | Lactamas como antagonistas de taquiquininas | |
| UY27092A1 (es) | Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen | |
| DE69906518D1 (de) | Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis | |
| GT200400174A (es) | Compuestos de bencimidazolona que tienen actividad agonista del receptor 5 ht4 | |
| BRPI0607926A2 (pt) | compostos espiro-oxindol e seus usos como agentes terapêuticos | |
| BR0008060A (pt) | Composições inibidoras de ciclooxigenase-2 tendo rápido inìcio de eficácia terapêutica | |
| AR020015A1 (es) | Composiciones de celecoxib | |
| DE60025604D1 (de) | Benzimidazol-derivate und diese enthaltende pharmazeutische zusammensetzungen | |
| NO20075353L (no) | Forbindelser, isomerer og farmasoytisk akseptable salter derav, som vanilloidreseptorantagonister, og farmasoytiske preparater inneholdende slike | |
| NO20081843L (no) | Farmasoytisk sammensetning for forbedret kognitiv funksjon | |
| AR063118A1 (es) | Derivados de sulfonamida-piperidina composiciones farmaceuticas que los contienen y usos en enfermedades y trastornos inflamatorios alergicos y respiratorios | |
| MX2020005518A (es) | Mezclas no racemicas y usos de las mismas. | |
| LV12291A (lv) | Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai | |
| MX2021014774A (es) | Formulaciones de liberacion modificada y usos de las mismas. | |
| BRPI0517227A (pt) | forma de dosagem oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, método de tratamento de uma doença ou condição | |
| HRP20130007T1 (hr) | Lijeäśenje kognitivnih poremeä†aja pomoä†u (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamida i njegovih farmaceutski prihvatljivih soli | |
| BRPI0415769A (pt) | alcanaminas de diidrobenzofuranila e composições farmacêuticas contendo-as | |
| CO2021000450A2 (es) | Forma de dosificación farmacéutica administrable por vía oral con liberación modificada | |
| EP2180884A4 (en) | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC ACTIVE SUBSTANCES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM | |
| KR101450345B1 (ko) | 특히 토가바이러스에 의해 유발된 염증성 증상의 예방 또는조기 치료를 위한 항히스타민제의 새로운 용도 | |
| AR120174A1 (es) | Inhibidores del factor d del complemento para administración oral | |
| UY30935A1 (es) | Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones. | |
| BR0105787A (pt) | Composição farmacêutica, uso de um composto farmacêutico, método para tratamento de distúrbios, composto farmacêutico e método para confeccionar um composto farmacêutico | |
| UY29445A1 (es) | Composiciones para la transmisión transmucosa oral de la metformina | |
| AR029666A1 (es) | Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20160617 |